Company: BOLT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058632
Chunk: 49

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 49
---
Executive Compensation—Severance and Change in Control Plan” below. (2) All of the option awards were granted with a per share exercise price equal to the fair market value of one share of our common stock on the date of grant, as determined in good faith by our Board or compensation committee. (3) This stock option is fully vested as of December 31, 2024. (4) This stock option is early exercisable and, to the extent shares subject to this option are issued and unvested as of a given date, such shares will remain subject to a right of repurchase held by us. As of December 31, 2024, the named executive officer had not early exercised the option. 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date (5) 1/36th of the shares subject to the option vest monthly measured from the vesting commencement date. (6) 1/36th of the shares subject to the option vest monthly measured from the vesting commencement date. The Schatzman Consulting Agreement terminated by its terms on April 15, 2025 and this option ceased vesting on such date. (7) 1/36th of the shares subject to the option vest monthly measured from the vesting commencement date. The Perez Consulting Agreement will terminate by its terms on July 15, 2025 and this option will cease vesting on such date.

<div align='center'>32</div>

Emerging Growth Company Status

We are an emerging growth company, as defined in the JOBS Act. As an emerging growth company, we are exempt from certain requirements related to executive compensation, including, but not limited to, the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Nonqualified Deferred Compensation

Our named executive officers did not participate in, or earn any benefits under, any nonqualified deferred compensation plan sponsored by us during the year ended December 31, 2024. Our Board may elect to provide our officers and other employees with nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.

Pension and Defined Benefit Plan Retirement Benefits

Our named